Plus Therapeutics Inc Dossier - Source-backed chat

Plus Therapeutics Inc

PSTVNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.25

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.87Price as of 31 Jul 2026

Data confidenceNot applicable

Market Cap $26.6M

Enterprise Value $23.6M

Shares Outstanding 6.9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Plus Therapeutics is a clinical-stage biopharmaceutical company uniquely positioned at the intersection of targeted radiotherapeutics and precision diagnostics for difficult-to-treat central nervous system (CNS) cancers. The company's lead therapeutic candidate, REYOBIQ (rhenium Re186 obisbemeda), targets high-unmet-need indications including leptomeningeal metastases (LM), recurrent glioblastoma (GBM), and pediatric brain cancers. Backed by substantial non-dilutive grant funding (including CPRIT, NIH/NCI, and DoD) and a commercial-stage diagnostic platform (CNSide) that is rapidly expanding its payer coverage, Plus Therapeutics offers a highly asymmetric risk-reward profile. While near-term capital risks and reverse-split dynamics have weighed on the stock price, the clinical progression of REYOBIQ toward pivotal trials and the commercial scale-up of CNSide represent powerful catalysts for long-term value creation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$36.00

High · most bullish analyst$57.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

In the bear case, CNSide commercial adoption is slower than expected due to reimbursement hurdles, delaying the path to operational breakeven. Clinical trials for REYOBIQ face enrollment delays or safety signals, pushing back regulatory milestones. With a high cash burn rate, the company is forced to raise highly dilutive equity capital under unfavorable market conditions, further depressing the stock price.

Base CaseCentral scenario

$8.0050%

In the base case, CNSide continues its steady commercial rollout, expanding payer coverage and increasing test volumes toward the 1,250 annualized order target. REYOBIQ's clinical trials progress in line with revised timelines, with dose optimization data for ReSPECT-LM delivered in late 2026 and ReSPECT-GBM Phase 2 enrollment completed by early 2027. The company utilizes its current cash runway (extending into mid-2027) to reach key regulatory milestones before requiring additional capital, supporting a moderate recovery in share value.

Bull CaseUpside scenario

$12.0030%

In the bull case, Plus Therapeutics successfully achieves its commercial targets for CNSide, expanding covered lives beyond 150 million and reaching operational breakeven ahead of the 2027 target. Simultaneously, REYOBIQ's ReSPECT-LM Phase 2 data in Q3 2026 demonstrates superior median overall survival compared to historical standards, prompting rapid FDA alignment on an accelerated approval pivotal trial design. Non-dilutive funding continues to offset clinical costs, and strategic pharmaceutical partnerships are secured for ex-US commercialization, driving significant valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Dual-pronged business model combining a high-potential radiotherapeutic pipeline (REYOBIQ) with a commercial-stage diagnostic platform (CNSide).
Strong non-dilutive funding support, including a $17.6M CPRIT grant, $3.0M NIH/NCI award, and $3.0M DoD grant, minimizing near-term equity dilution.
Rapidly expanding payer coverage for CNSide, reaching approximately 81 million covered lives as of Q1 2026, with a clear pathway to Medicare reimbursement.
Robust multi-partner supply chain established with Radiomedix, SpectronRx, and Telix Pharmaceuticals to support late-stage clinical and commercial manufacturing.

Key Investment Risks

Clinical development risk inherent to early-stage oncology therapies, with potential for enrollment delays or unfavorable efficacy/safety outcomes.
Financial risk and high cash burn, with the company currently operating at a net loss and requiring commercial scale-up or additional financing to sustain operations beyond mid-2027.
Market liquidity and volatility risks following the company's 1-for-25 reverse stock split in early 2026.

Thesis Invalidation Triggers

Failure to define an optimal dose or deliver positive efficacy data in the ReSPECT-LM Phase 2 trial by the end of 2026.
Significant delays in CNSide commercial adoption, resulting in a failure to reach operational breakeven by 2027.
Inability to secure additional non-dilutive funding or strategic partnerships, leading to severe capital constraints before mid-2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.